SCHEMBL5152843

SCHEMBL5152843

CSc1ccc(C2SCC(=O)N2Cc2ccc(F)cc2)cc1

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 5/20 0.75
KMT2A Q03164 5/20 0.75
MAPT P10636 1/20 0.67
CYP2C9 P11712 1/20 0.51
CYP2C19 P33261 1/20 0.51
POLB P06746 1/20 0.51
HPGD P15428 3/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
L3MBTL1 Q9Y468 2/20 0.48
GAA P10253 2/20 0.48
ATM Q13315 1/20 0.48
LMNA P02545 1/20 0.47
ALOX12 P18054 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
HTT P42858 1/20 0.47
PTGS1 P23219 1/20 0.46
PTGS2 P35354 1/20 0.46
KDM4E B2RXH2 1/20 0.46
ALDH1A1 P00352 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5152438 0.88 MEN1 (0.72) MEN1KMT2AMAPTCYP2C9CYP2C19
SCHEMBL5150098 0.87 MEN1 (0.57) MEN1KMT2AMAPTCYP2C9CYP2C19
SCHEMBL19306397 0.84 KMT2A (0.78) MEN1KMT2AMAPTCYP2C9CYP2C19
SCHEMBL6919581 0.83 MEN1 (0.65) MEN1KMT2AMAPTCYP2C9CYP2C19
SCHEMBL19306513 0.80 MEN1 (0.71) MEN1KMT2AMAPTCYP2C9CYP2C19
SCHEMBL19305954 0.79 MEN1 (0.81) MEN1KMT2AMAPTCYP2C9CYP2C19
SCHEMBL5155057 0.78 KMT2A (0.67) MEN1KMT2AMAPTCYP2C9CYP2C19
SCHEMBL5155073 0.75 MEN1 (0.55) MEN1KMT2AMAPTCYP2C9CYP2C19
SCHEMBL5151573 0.75 MAPT (0.67) MEN1KMT2AMAPTCYP2C9CYP2C19
SCHEMBL5151517 0.74 PTGS1 (0.51) MEN1KMT2AGAALMNAPTGS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7223754-B2 Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating lower urinary tract and related disorders DYNOGEN PHARMACEUTICALS, INC. (US) 2007-05-29 US disclosed
US-20070066597-A1 Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating lower urinary tract and related disorders DYNOGEN PHARMACEUTICALS, INC. (US) 2007-03-22 US disclosed
US-20050148587-A1 Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating lower urinary tract and related disorders DYNOGEN PHARMACEUTICALS, INC. (US) 2005-07-07 US disclosed
US-20050113421-A1 Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating non-inflammatory gastrointestinal tract disorders DYNOGEN PHARMACEUTICALS, INC. (US) 2005-05-26 US disclosed
WO-2004017965-A1 1,3-THIAZOLIN-4-ONES AS THERAPEUTIC COMPOUNDS IN THE TREATMENT OF PAIN IONIX PHARMACEUTICALS LIMITED (GB) 2004-03-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050113421-A1 Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating non-inflammatory gastrointestinal tract disorders TRPV2, RYR2, VDAC2 MEN1 3532/4885KMT2A 4084/4885MAPT 3411/4885
US-20070066597-A1 Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating lower urinary tract and related disorders RYR2, CACNB2, CACNA1I MEN1 3820/4885KMT2A 3401/4885MAPT 2432/4885
US-20050148587-A1 Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating lower urinary tract and related disorders RYR2, CACNB2, CACNA1I MEN1 3820/4885KMT2A 3401/4885MAPT 2432/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.